癌症进展
癌癥進展
암증진전
Oncology Progress
2015年
5期
545-549,557
,共6页
郑艳彬%何鸿鸣%杨瑜%林剑扬%王杰松%邹思平
鄭豔彬%何鴻鳴%楊瑜%林劍颺%王傑鬆%鄒思平
정염빈%하홍명%양유%림검양%왕걸송%추사평
淋巴瘤%胃肿瘤%预后因素%治疗
淋巴瘤%胃腫瘤%預後因素%治療
림파류%위종류%예후인소%치료
lymphoma%gastric neoplasms%prognostic factors%therapy
目的：探讨原发性胃弥漫大B细胞淋巴瘤（primary gastric diffuse large B-cell lymphoma，PG-DLBCL）的预后影响因素。方法回顾性分析56例PG-DLBCL患者的临床资料及随访数据，采用Kaplan-Meier法估算患者的生存时间，采用Cox比例风险模型进行预后影响因素分析。结果56例PG-DLBCL患者的1年、2年、3年无事件生存率分别为73.2%，71.3%，68.8%，平均无事件生存时间（event-free survival，EFS）为69个月；1年、2年、3年总生存率分别为81.8%，73.3%，70.5%，平均总生存时间（overall survival，OS）为72个月。化疗联合放疗组的平均EFS比单纯化疗组长，差异有统计学意义（P﹦0.039）；不同的Musshoff分期、LDH水平、淋巴瘤国际预后指数（international prognostic index，IPI）评分、β2微球蛋白值、美国东部肿瘤协作组（Eastern Cooperative On-cology Group，ECOG）体能状态（performance status，PS）评分、有无巨块对EFS及OS均有明确的影响（P＜0.05）。影响EFS及OS的独立预后因素为LDH水平及ECOG评分。结论对PG-DLBCL患者推荐采取以化疗为主的非手术治疗，LDH升高及PS评分高是预后不良的重要指标。
目的：探討原髮性胃瀰漫大B細胞淋巴瘤（primary gastric diffuse large B-cell lymphoma，PG-DLBCL）的預後影響因素。方法迴顧性分析56例PG-DLBCL患者的臨床資料及隨訪數據，採用Kaplan-Meier法估算患者的生存時間，採用Cox比例風險模型進行預後影響因素分析。結果56例PG-DLBCL患者的1年、2年、3年無事件生存率分彆為73.2%，71.3%，68.8%，平均無事件生存時間（event-free survival，EFS）為69箇月；1年、2年、3年總生存率分彆為81.8%，73.3%，70.5%，平均總生存時間（overall survival，OS）為72箇月。化療聯閤放療組的平均EFS比單純化療組長，差異有統計學意義（P﹦0.039）；不同的Musshoff分期、LDH水平、淋巴瘤國際預後指數（international prognostic index，IPI）評分、β2微毬蛋白值、美國東部腫瘤協作組（Eastern Cooperative On-cology Group，ECOG）體能狀態（performance status，PS）評分、有無巨塊對EFS及OS均有明確的影響（P＜0.05）。影響EFS及OS的獨立預後因素為LDH水平及ECOG評分。結論對PG-DLBCL患者推薦採取以化療為主的非手術治療，LDH升高及PS評分高是預後不良的重要指標。
목적：탐토원발성위미만대B세포림파류（primary gastric diffuse large B-cell lymphoma，PG-DLBCL）적예후영향인소。방법회고성분석56례PG-DLBCL환자적림상자료급수방수거，채용Kaplan-Meier법고산환자적생존시간，채용Cox비례풍험모형진행예후영향인소분석。결과56례PG-DLBCL환자적1년、2년、3년무사건생존솔분별위73.2%，71.3%，68.8%，평균무사건생존시간（event-free survival，EFS）위69개월；1년、2년、3년총생존솔분별위81.8%，73.3%，70.5%，평균총생존시간（overall survival，OS）위72개월。화료연합방료조적평균EFS비단순화료조장，차이유통계학의의（P﹦0.039）；불동적Musshoff분기、LDH수평、림파류국제예후지수（international prognostic index，IPI）평분、β2미구단백치、미국동부종류협작조（Eastern Cooperative On-cology Group，ECOG）체능상태（performance status，PS）평분、유무거괴대EFS급OS균유명학적영향（P＜0.05）。영향EFS급OS적독립예후인소위LDH수평급ECOG평분。결론대PG-DLBCL환자추천채취이화료위주적비수술치료，LDH승고급PS평분고시예후불량적중요지표。
Objective To analyze the prognosis of primary gastric diffuse large B-cell lymphoma (PG-DLBCL). Method The clinical profiles and follow-up datas of 56 patients with PG-DLBCL were retrospectively analyzed. Ka-plan-Meier was applied to estimate the survival time of all patients, while Cox proportional hazard model was used to investigate the association between clinicopathological features with prognosis. Result The EFS (event-free survival) rate at 1-, 2-, and 3 years were 73.2%, 71.3%, and 68.8%, respectively, with a mean EFS of 69 months. The OS (overall survival) rate at 1-, 2-, and 3 years were 81.8%, 73.3%, and 70.5%, respectively, with a mean OS of 72 months. Therefore the mean EFS of chemotherapy + radiotherapy group is significantly longer than that of the radio-therapy alone group (P =0.039). Univariate analysis revealed that either EFS or OS was significantly influenced by Musshoff stage, LDH level, international prognostic index score, β2 microglobulin value, ECOG PS score, presence of giant mass (P<0.05). Cox regression model revealed that only LDH level and ECOG score were independent prognos-tic factors for EFS and OS. Conclusion Non-surgical treatment, as chemotherapy, is recommended for PG-DLBCL patients. LDH level and PS score are independent prognostic factors for PG-DLBCL.
